$FATE
FATE THERAPEUTICS INC Stock $fate

$fate Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000110465914038138 Filed on May 13, 2014

Income Statement

Concept	2014 Q2	2014 Q1	2013 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.070M	$2.420M	$1.870M
YoY Change	38.93%	86.15%	46.09%
% of Gross Profit
Research & Development	$3.970M	$4.522M	$3.030M
YoY Change	29.32%	78.66%	-10.88%
% of Gross Profit
Depreciation & Amortization	$140.0K	$123.0K	$130.0K
YoY Change	0.0%	-21.66%	-18.75%
% of Gross Profit
Operating Expenses	$6.040M	$6.937M	$4.902M
YoY Change	32.49%	81.22%	4.59%
Operating Profit		-$6.937M
YoY Change		106.7%
Interest Expense	-$30.00K	$43.00K	-$840.0K
YoY Change	-97.64%	-57.0%
% of Operating Profit
Other Income/Expense, Net		-$43.00K
YoY Change		-77.6%
Pretax Income	-$6.070M	-$6.980M	-$5.740M
YoY Change	9.76%	96.62%	37.98%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$6.067M	-$6.980M	-$5.739M
YoY Change	9.63%	96.73%	38.12%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	-$296.5K	-$343.0K	-$299.6K
COMMON SHARES
Basic Shares Outstanding	20.51M shares	20.44M shares	20.36M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q2	2014 Q1	2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$42.00M	$47.90M	$54.00M
YoY Change	1135.29%	941.3%	493.41%
Cash & Equivalents	$42.00M	$47.88M	$54.04M
Short-Term Investments
Other Short-Term Assets	$200.0K	$400.0K	$600.0K
YoY Change	-71.43%	-33.33%	-14.29%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$42.20M	$48.26M	$54.65M
YoY Change	929.27%	810.62%	458.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.200M	$1.264M	$810.0K
YoY Change	33.33%	26.4%	-30.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$100.0K	$100.0K	$100.0K
YoY Change	-91.67%	0.0%	0.0%
Total Long-Term Assets	$1.400M	$1.386M	$932.0K
YoY Change	-33.33%	26.0%	-27.36%
TOTAL ASSETS
Total Short-Term Assets	$42.20M	$48.26M	$54.65M
Total Long-Term Assets	$1.400M	$1.386M	$932.0K
Total Assets	$43.60M	$49.65M	$55.58M
YoY Change	603.23%	675.77%	401.83%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.000M	$1.330M	$682.0K
YoY Change	-67.74%	-16.88%	-44.46%
Accrued Expenses	$1.900M	$1.641M	$2.039M
YoY Change			96.06%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%
Long-Term Debt Due	$700.0K	$1.240M	$1.732M
YoY Change	-65.0%	-38.0%	-10.77%
Total Short-Term Liabilities	$3.800M	$4.354M	$4.600M
YoY Change	-54.76%	6.2%	-5.15%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Long-Term Liabilities	$100.0K	$100.0K	$100.0K
YoY Change	-95.0%	-88.89%	-87.5%
Total Long-Term Liabilities	$100.0K	$100.0K	$100.0K
YoY Change	-96.3%	-95.24%	-94.23%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.800M	$4.354M	$4.600M
Total Long-Term Liabilities	$100.0K	$100.0K	$100.0K
Total Liabilities	$3.900M	$4.500M	$4.700M
YoY Change	-64.86%	-27.42%	-28.59%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock		$20.00K	$20.00K
YoY Change			1900.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$39.60M	$45.18M	$50.85M
YoY Change
Total Liabilities & Shareholders Equity	$43.60M	$49.65M	$55.58M
YoY Change	603.23%	675.77%	401.83%

Cashflow Statement

Concept	2014 Q2	2014 Q1	2013 Q4
OPERATING ACTIVITIES
Net Income	-$6.067M	-$6.980M	-$5.739M
YoY Change	9.63%	96.73%	38.12%
Depreciation, Depletion And Amortization	$140.0K	$123.0K	$130.0K
YoY Change	0.0%	-21.66%	-18.75%
Cash From Operating Activities	-$5.480M	-$5.260M	-$4.570M
YoY Change	61.65%	33.84%	34.81%
INVESTING ACTIVITIES
Capital Expenditures	-$20.00K	$398.0K	-$150.0K
YoY Change	-66.67%	5585.71%	-50.0%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities	-$20.00K	-$400.0K	-$150.0K
YoY Change	-66.67%	3900.0%	-50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		-$2.000K
YoY Change
Debt Paid & Issued, Net		$500.0K
YoY Change		0.0%
Cash From Financing Activities	-360.0K	-500.0K	39.68M
YoY Change	-116.29%	0.0%	442.82%
NET CHANGE
Cash From Operating Activities	-5.480M	-5.260M	-4.570M
Cash From Investing Activities	-20.00K	-400.0K	-150.0K
Cash From Financing Activities	-360.0K	-500.0K	39.68M
Net Change In Cash	-5.860M	-6.160M	34.96M
YoY Change	372.58%	38.74%	865.75%
FREE CASH FLOW
Cash From Operating Activities	-$5.480M	-$5.260M	-$4.570M
Capital Expenditures	-$20.00K	$398.0K	-$150.0K
Free Cash Flow	-$5.460M	-$5.658M	-$4.420M
YoY Change	63.96%	43.71%	43.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-3548000	USD
CY2013Q1	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	21000	USD
CY2014Q1	fate	Initial Fair Value And Adjustment Of Exchangeable Shares InitialFairValueAndAdjustmentOfExchangeableShares	375000	USD
CY2014Q1	dei	Entity Registrant Name EntityRegistrantName	FATE THERAPEUTICS INC
CY2014Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001434316
CY2014Q1	dei	Document Type DocumentType	10-Q
CY2014Q1	dei	Document Period End Date DocumentPeriodEndDate	2014-03-31
CY2014Q1	dei	Amendment Flag AmendmentFlag	false
CY2014Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014Q1	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2014Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20514567	shares
CY2014Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2014Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-size:10.0pt;font-family:Times New Roman;"> <p style="MARGIN: 0in 0in 0pt;"><b><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold;" size="2">Use of Estimates</font></b></p> <p style="MARGIN: 0in 0in 0pt;"> </p> <p style="TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt;"><font style="FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt;" size="2">The Company’s consolidated financial statements are prepared in accordance with United States generally accepted accounting principles (“GAAP”). The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the valuation of equity awards and accrued expenses. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</font></p> </div>
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q1	fate	Number Of Platforms To Enhance Therapeutic Potential Of Adult Stem Cells NumberOfPlatformsToEnhanceTherapeuticPotentialOfAdultStemCells	2	item
CY2014Q1	us-gaap	Revenue Recognition Milestone Method Factors RevenueRecognitionMilestoneMethodFactors	(i) persuasive evidence that an agreement exists; (ii) delivery of the products and/or services has occurred; (iii) the selling price is fixed or determinable; and (iv) collectibility is reasonably assured
CY2013Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7666667	shares
CY2013Q4	us-gaap	Equity Issuance Per Share Amount EquityIssuancePerShareAmount	6.00
CY2013Q4	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	46000000	USD
CY2013Q4	fate	Net Proceeds From Issuance Initial Public Offering NetProceedsFromIssuanceInitialPublicOffering	40480000	USD
CY2013Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	7229590	shares
CY2013Q4	us-gaap	Debt Conversion Original Debt Amount1 DebtConversionOriginalDebtAmount1	22100000	USD
CY2013Q4	fate	Stock Issued During Period Shares Conversion Of Convertible Notes Into Common Stock StockIssuedDuringPeriodSharesConversionOfConvertibleNotesIntoCommonStock	3679401	shares
CY2013Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	300000	USD
CY2013Q4	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	1700000	USD
CY2013Q4	fate	Common Stock Issuable Upon Redemption Of Exchangeable Shares CommonStockIssuableUponRedemptionOfExchangeableShares	480763	shares
CY2013Q4	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	400000	USD
CY2013Q4	fate	Exchangeable Shares Of Subsidiary For Redemption ExchangeableSharesOfSubsidiaryForRedemption	900000	shares
CY2013Q4	fate	Class Of Warrant Or Right Warrants Issued To Purchase Shares Of Convertible Preferred Stock Converted ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfConvertiblePreferredStockConverted	230000	shares
CY2013Q4	fate	Class Of Warrant Or Right Warrants Issued To Purchase Shares Of Common Stock On Conversion ClassOfWarrantOrRightWarrantsIssuedToPurchaseSharesOfCommonStockOnConversion	36074	shares
CY2014Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0	USD
CY2014Q1	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0	USD
CY2014Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1250000	USD
CY2013Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1750000	USD
CY2014Q1	fate	Long Term Debt Gross Current LongTermDebtGrossCurrent	1250000	USD
CY2013Q4	fate	Long Term Debt Gross Current LongTermDebtGrossCurrent	1750000	USD
CY2014Q1	fate	Debt Instrument Discount Current DebtInstrumentDiscountCurrent	10000	USD
CY2013Q4	fate	Debt Instrument Discount Current DebtInstrumentDiscountCurrent	18000	USD
CY2014Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	1240000	USD
CY2013Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1732000	USD
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	871000	USD
CY2013Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	75000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-6980000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-93489000	USD
CY2014Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	123000	USD
CY2013Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	157000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2631000	USD
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	57000	USD
CY2014Q1	us-gaap	Share Based Compensation ShareBasedCompensation	871000	USD
CY2013Q1	us-gaap	Share Based Compensation ShareBasedCompensation	75000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	3194000	USD
CY2014Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	8000	USD
CY2013Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	18000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	543000	USD
CY2014Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	10000	USD
CY2013Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	22000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	1179000	USD
CY2014Q1	us-gaap	Straight Line Rent StraightLineRent	9000	USD
CY2013Q1	us-gaap	Straight Line Rent StraightLineRent	59000	USD
	us-gaap	Straight Line Rent StraightLineRent	-179000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-6155000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-4440000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	47881000	USD
CY2013Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	500000	USD
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	47881000	USD
CY2013Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4647000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54036000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9087000	USD
CY2013Q1	us-gaap	Contracts Revenue ContractsRevenue	209000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6829000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	58646000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-502000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-500000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	131218000	USD
CY2013Q1	fate	Initial Fair Value And Adjustment Of Exchangeable Shares InitialFairValueAndAdjustmentOfExchangeableShares	105000	USD
	fate	Initial Fair Value And Adjustment Of Exchangeable Shares InitialFairValueAndAdjustmentOfExchangeableShares	3693000	USD
CY2013Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-12000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-35000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-135000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-332000	USD
CY2014Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-304000	USD
CY2013Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-49000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1673000	USD
CY2014Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	43000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3890000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5255000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3933000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-79364000	USD
CY2014Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	398000	USD
CY2013Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4059000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	208000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	122000	USD
CY2014Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-398000	USD
CY2013Q1	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-7000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-3973000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	-2000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	292000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	7000	USD
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	32236000	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	6400000	USD
CY2014Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	500000	USD
	us-gaap	Contracts Revenue ContractsRevenue	2927000	USD
CY2013Q1	us-gaap	Revenue From Grants RevenueFromGrants	263000	USD
	us-gaap	Revenue From Grants RevenueFromGrants	2084000	USD
CY2013Q1	us-gaap	Sales Revenue Net SalesRevenueNet	472000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	5011000	USD
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4522000	USD
CY2013Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2531000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	61508000	USD
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2415000	USD
CY2013Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1297000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33125000	USD
CY2014Q1	us-gaap	Operating Expenses OperatingExpenses	6937000	USD
CY2013Q1	us-gaap	Operating Expenses OperatingExpenses	3828000	USD
	us-gaap	Operating Expenses OperatingExpenses	94633000	USD
CY2014Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-6937000	USD
CY2013Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3356000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-89622000	USD
CY2013Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	192000	USD
CY2014Q1	us-gaap	Interest Expense InterestExpense	43000	USD
CY2013Q1	us-gaap	Interest Expense InterestExpense	100000	USD
	us-gaap	Interest Expense InterestExpense	2684000	USD
	us-gaap	Investment Tax Credit InvestmentTaxCredit	-1231000	USD
CY2013Q1	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	105000	USD
	fate	Fair Value Adjustment Of Exchangeable Shares FairValueAdjustmentOfExchangeableShares	2309000	USD
CY2014Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-43000	USD
CY2013Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-192000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3867000	USD
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-2.92
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	20346856	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1213286	shares
CY2014Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	382000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	615000	USD
CY2014Q1	us-gaap	Assets Current AssetsCurrent	48263000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	54651000	USD
CY2014Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1264000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	810000	USD
CY2014Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	122000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	122000	USD
CY2014Q1	us-gaap	Assets Assets	49649000	USD
CY2013Q4	us-gaap	Assets Assets	55583000	USD
CY2014Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1330000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	682000	USD
CY2014Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1641000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2039000	USD
CY2014Q1	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	61000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	53000	USD
CY2014Q1	fate	Repurchase Liability For Unvested Equity Awards Current RepurchaseLiabilityForUnvestedEquityAwardsCurrent	82000	USD
CY2013Q4	fate	Repurchase Liability For Unvested Equity Awards Current RepurchaseLiabilityForUnvestedEquityAwardsCurrent	94000	USD
CY2014Q1	us-gaap	Liabilities Current LiabilitiesCurrent	4354000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4600000	USD
CY2014Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	118000	USD
CY2013Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	135000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q1	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2014Q1	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2014Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	138646000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	137337000	USD
CY2014Q1	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	93489000	USD
CY2013Q4	us-gaap	Development Stage Enterprise Deficit Accumulated During Development Stage DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage	86509000	USD
CY2014Q1	us-gaap	Stockholders Equity StockholdersEquity	45177000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	50848000	USD
CY2014Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49649000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55583000	USD
CY2014Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2014Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20463849	shares
CY2014Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20463849	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20434080	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20434080	shares
CY2014Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	2500000	shares
CY2014Q1	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	88043	shares
CY2013Q1	fate	Shares Attributable To Share Based Payment Arrangements Excluded From Weighted Average Number Of Shares Outstanding SharesAttributableToShareBasedPaymentArrangementsExcludedFromWeightedAverageNumberOfSharesOutstanding	120822	shares
	fate	Net Proceeds From Issuance Initial Public Offering NetProceedsFromIssuanceInitialPublicOffering	40480000	USD
CY2013Q1	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9200000	shares
CY2014Q1	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	2200000	shares
CY2014Q1	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	100000	USD
CY2014Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	2100000	USD

Files In Submission

Name	View Source	Status
0001104659-14-038138-index-headers.html	Edgar Link	pending
0001104659-14-038138-index.html	Edgar Link	pending
0001104659-14-038138.txt	Edgar Link	pending
0001104659-14-038138-xbrl.zip	Edgar Link	pending
a14-9191_110q.htm	Edgar Link	pending
a14-9191_1ex31d1.htm	Edgar Link	pending
a14-9191_1ex31d2.htm	Edgar Link	pending
a14-9191_1ex32d1.htm	Edgar Link	pending
a14-9191_1ex32d2.htm	Edgar Link	pending
fate-20140331.xml	Edgar Link	completed
fate-20140331.xsd	Edgar Link	pending
fate-20140331_cal.xml	Edgar Link	unprocessable
fate-20140331_def.xml	Edgar Link	unprocessable
fate-20140331_lab.xml	Edgar Link	unprocessable
fate-20140331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FATE
FATE THERAPEUTICS INC Stock $fate

2014 Q2 Form 10-Q Financial Statement

#000110465914038138 Filed on May 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE FATE THERAPEUTICS INC Stock $fate

2014 Q2 Form 10-Q Financial Statement

#000110465914038138 Filed on May 13, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FATE
FATE THERAPEUTICS INC Stock $fate